Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 4/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL864990 | 0.84 | CCNT1 (0.41) | CCNT1CYP11B2BTKSCN9AOPRL1 | |
| Hydrochloric Acid SCHEMBL864992 | 0.84 | CCNT1 (0.41) | CCNT1CYP11B2BTKSCN9AOPRL1 | |
| Hydrochloric Acid SCHEMBL864991 | 0.84 | CCNT1 (0.41) | CCNT1CYP11B2BTKSCN9AOPRL1 | |
| SCHEMBL2114949 | 0.82 | CCNT1 (0.37) | CCNT1CYP11B2BTKSCN9AOPRL1 | |
| SCHEMBL2115271 | 0.80 | POLB (0.39) | PDCD1CD274 | |
| SCHEMBL2114950 | 0.79 | CCNT1 (0.38) | CCNT1CYP11B2BTKSCN9AOPRL1 | |
| SCHEMBL15899855 | 0.77 | CNR2 (0.39) | — | |
| SCHEMBL15899849 | 0.77 | CNR2 (0.39) | — | |
| SCHEMBL863822 | 0.76 | PIK3CD (0.42) | CCNT1BTK | |
| SCHEMBL863821 | 0.76 | PIK3CD (0.42) | CCNT1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | CCNT1 2033/4885CYP11B2 1248/4885GRIN2B 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.